Compare Liberty Global Ltd Class C (LBTYK) vs Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) (TAK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Liberty Global Ltd Class C vs Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) — how do they compare? Liberty Global Ltd Class C trades at $8.52 (market cap $3.06B), while Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) trades at $18.73 (market cap $58.74B). The key difference: Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) is far larger — about 19.2× Liberty Global Ltd Class C's market cap, and Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) pays a 3.33% dividend while Liberty Global Ltd Class C pays none. Which is the better fit depends on your goals — on Pluang, investors hold Liberty Global Ltd Class C for 21 Days and Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) for 1 Days on average.
| LBTYK | TAK | |
|---|---|---|
Market Cap | $3.06B | $58.74B |
Volume | 2,508,956 | 3,110,994 |
Sector | Media | Health |
52-Week High | $12.67 | $19.05 |
52-Week Low | $8.75 | $13.23 |
Typical Hold Time | 21 Days | 1 Days |
Enterprise Value | $9.72B | $86.65B |
Dividend Yield | — | 3.33% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Liberty Global (LBTYK) trades at $8.52, down 4.48% amid bearish technical signals. The stock shows mixed fundamentals with strong gross margins of 67.17% but significant net losses. Recent earnings have been volatile, with Q1 2026 beating expectations but Q2 missing. The company is progressing with strategic initiatives including the Ziggo Group spin-off planned for 2027 and an AI partnership with Sierra.
Despite current losses, analyst consensus remains bullish with a $12.67 price target, suggesting 49% upside. Key risks include execution of the Ziggo listing and sustained profitability challenges. The cash position and asset monetization provide downside support, while the planned 2027 value-unlock event represents the primary growth catalyst.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Liberty Global Ltd Class C
Liberty Global is a world leader in converged broadband, video, and mobile communications. It operates large-scale fiber and 5G networks across Europe, providing essential digital services to millions of customers.
Read more on LBTYK →About Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)
Takeda is a Japanese pharmaceutical company developing medicines across areas including gastrointestinal disease, rare diseases, neuroscience, oncology, and plasma-derived therapies.
Read more on TAK →
